{
    "q": [
        {
            "docid": "1581752_26",
            "document": "Protein design . Several algorithms have been developed specifically for the protein design problem. These algorithms can be divided into two broad classes: exact algorithms, such as dead-end elimination, that lack runtime guarantees but guarantee the quality of the solution; and heuristic algorithms, such as Monte Carlo, that are faster than exact algorithms but have no guarantees on the optimality of the results. Exact algorithms guarantee that the optimization process produced the optimal according to the protein design model. Thus, if the predictions of exact algorithms fail when these are experimentally validated, then the source of error can be attributed to the energy function, the allowed flexibility, the sequence space or the target structure (e.g., if it cannot be designed for)",
            "score": 78.83851408958435
        },
        {
            "docid": "2606518_25",
            "document": "Macromolecular docking . The ultimate goal in protein\u2013protein docking is to select the ideal ranking solution according to a scoring scheme that would also give an insight into the affinity of the complex. Such a development would drive \"in silico\" protein engineering, computer-aided drug design and/or high-throughput annotation of which proteins bind or not (annotation of interactome). Several scoring functions have been proposed for binding affinity / free energy prediction. However the correlation between experimentally determined binding affinities and the predictions of nine commonly used scoring functions have been found to be nearly orthogonal (R ~ 0). It was also observed that some components of the scoring algorithms may display better correlation to the experimental binding energies than the full score, suggesting that a significantly better performance might be obtained by combining the appropriate contributions from different scoring algorithms. Experimental methods for the determination of binding affinities are: surface plasmon resonance (SPR), F\u00f6rster resonance energy transfer, radioligand-based techniques, isothermal titration calorimetry (ITC), microscale thermophoresis (MST) or spectroscopic measurements and other fluorescence techniques.",
            "score": 67.40450859069824
        },
        {
            "docid": "4007999_13",
            "document": "Immunogenicity . De-immunization by epitope modification is a strategy for reducing immunogenicity based on disruption of HLA binding, an underlying requirement for T cell stimulation. The idea of rational epitope modification is rooted in the natural process that occurs when tumor cells and pathogens evolve to escape immune pressure by accumulating mutations that reduce the binding of their constituent epitopes to host HLA, rendering the host cell unable to \u201csignal\u201d to T cells the presence of the tumor or pathogen. Deimmunized protein therapeutics are now entering the clinic; initial results appear to support this approach to reducing immunogenicity risk. Several methods exist for deimmunization by epitope modification for reduced immunologic potential in-vitro, in-vivo and ex-vivo.",
            "score": 67.7914309501648
        },
        {
            "docid": "216104_21",
            "document": "Protein engineering . The main challenges of designing high quality mutant libraries have shown significant progress in the recent past. This progress has been in the form of better descriptions of the effects of mutational loads on protein traits. Also computational approaches have showed large advances in the innumerably large sequence space to more manageable screenable sizes, thus creating smart libraries of mutants. Library size has also been reduced to more screenable sizes by the identification of key beneficial residues using algorithms for systematic recombination. Finally a significant step forward toward efficient reengineering of enzymes has been made with the development of more accurate statistical models and algorithms quantifying and predicting coupled mutational effects on protein functions.",
            "score": 65.52622818946838
        },
        {
            "docid": "34567821_4",
            "document": "Critical Assessment of Function Annotation . The genome of an organism may consist of hundreds to tens of thousands of genes, which encode for hundreds of thousands of different protein sequences. Due to the relatively low cost of genome sequencing, determining gene and protein sequences is fast and inexpensive. Thousands of species have been sequenced so far, yet many of the proteins are not well characterized. The process of experimentally determining the role of a protein in the cell, is an expensive and time consuming task. Further, even when functional assays are performed they are unlikely to provide complete insight into protein function. Therefore it has become important to use computational tools in order to functionally annotate proteins. There are several computational methods of protein function prediction that can infer protein function using a variety of biological and evolutionary data, but there is significant room for improvement. Accurate prediction of protein function can have longstanding implications on biomedical and pharmaceutical research.",
            "score": 69.92847681045532
        },
        {
            "docid": "9783078_4",
            "document": "Proteins@home . \"The amino acid sequence of a protein determines its three-dimensional structure, or 'fold'. Conversely, the three-dimensional structure is compatible with a large, but limited set of amino acid sequences. Enumerating the allowed sequences for a given fold is known as the 'inverse protein folding problem'. We are working to solve this problem for a large number of known protein folds (a representative subset: about 1500 folds). The most expensive step is to build a database of energy functions that describe all these structures. For each structure, we consider all possible sequences of amino acids. Surprisingly, this is computationally tractable, because our energy functions are sums over pairs of interactions. Once this is done, we can explore the space of amino acid sequences in a fast and efficient way, and retain the most favorable sequences. This large-scale mapping of protein sequence space will have applications for predicting protein structure and function, for understanding protein evolution, and for designing new proteins. By joining the project, you will help to build the database of energy functions and advance an important area of science with potential biomedical applications.\"",
            "score": 73.23689985275269
        },
        {
            "docid": "216104_4",
            "document": "Protein engineering . In rational protein design, a scientist uses detailed knowledge of the structure and function of a protein to make desired changes. In general, this has the advantage of being inexpensive and technically easy, since site-directed mutagenesis methods are well-developed. However, its major drawback is that detailed structural knowledge of a protein is often unavailable, and, even when available, it can be very difficult to predict the effects of various mutations since structural information most often provide a static picture of a protein structure. However, programs such as Folding@home and Foldit have utilized crowdsourcing techniques in order to gain insight into the folding motifs of proteins.  Computational protein design algorithms seek to identify novel amino acid sequences that are low in energy when folded to the pre-specified target structure. While the sequence-conformation space that needs to be searched is large, the most challenging requirement for computational protein design is a fast, yet accurate, energy function that can distinguish optimal sequences from similar suboptimal ones.",
            "score": 76.59115076065063
        },
        {
            "docid": "216104_76",
            "document": "Protein engineering . Advances in semi-rational enzyme engineering and de novo enzyme design provide researchers with powerful and effective new strategies to manipulate biocatalysts. Integration of sequence and structure based approaches in library design has proven to be a great guide for enzyme redesign. Generally, current computational de novo and redesign methods do not compare to evolved variants in catalytic performance. Although experimental optimization may be produced using directed evolution, further improvements in the accuracy of structure predictions and greater catalytic ability will be achieved with improvements in design algorithms. Further functional enhancements may be included in future simulations by integrating protein dynamics.",
            "score": 70.89920425415039
        },
        {
            "docid": "27947144_5",
            "document": "Minimotif Miner . Typical results of MnM predict more than 50 new minimotifs for a protein query. A major limitation in this type of analysis is that the low sequence complexity of short minimotifs produces false positive predictions where the sequence occurs in a protein by random chance and not because it contains the predicted function. MnM 3.0 introduces a library of advanced heuristics and filters, which enable vast reduction of false positive predictions. These filters use minimotif complexity, protein surface location, molecular processes, cellular processes, protein-protein interactions, and genetic interactions. We recently combined all of these heuristics into a single, compound filter which makes significant progress toward solving this problem with high accuracy of minimotif prediction as measured by a performance benchmarking study which evaluated both sensitivity and specificity.",
            "score": 63.27837872505188
        },
        {
            "docid": "216104_20",
            "document": "Protein engineering . Natural Darwinian evolution can be effectively imitated in the lab toward tailoring protein properties for diverse applications, including catalysis. Many experimental technologies exist to produce large and diverse protein libraries and for screening or selecting folded, functional variants. Folded proteins arise surprisingly frequently in random sequence space, an occurrence exploitable in evolving selective binders and catalysts. While more conservative than direct selection from deep sequence space, redesign of existing proteins by random mutagenesis and selection/screening is a particularly robust method for optimizing or altering extant properties. It also represents an excellent starting point for achieving more ambitious engineering goals. Allying experimental evolution with modern computational methods is likely the broadest, most fruitful strategy for generating functional macromolecules unknown to nature.",
            "score": 79.90781688690186
        },
        {
            "docid": "29467449_4",
            "document": "Protein function prediction . While techniques such as microarray analysis, RNA interference, and the yeast two-hybrid system can be used to experimentally demonstrate the function of a protein, advances in sequencing technologies have made the rate at which proteins can be experimentally characterized much slower than the rate at which new sequences become available. Thus, the annotation of new sequences is mostly by \"prediction\" through computational methods, as these types of annotation can often be done quickly and for many genes or proteins at once. The first such methods inferred function based on homologous proteins with known functions (homology-based function prediction). The development of context-based and structure based methods have expanded what information can be predicted, and a combination of methods can now be used to get a picture of complete cellular pathways based on sequence data. The importance and prevalence of computational prediction of gene function is underlined by an analysis of 'evidence codes' used by the GO database: as of 2010, 98% of annotations were listed under the code IEA (inferred from electronic annotation) while only 0.6% were based on experimental evidence.",
            "score": 70.9705445766449
        },
        {
            "docid": "1581752_3",
            "document": "Protein design . Rational protein design dates back to the mid-1970s, although initial protein design approaches were based mostly on sequence composition and did not account for specific interactions between side-chains at the atomic level. Recently, however, improvements in molecular force fields, protein design algorithms, and structural bioinformatics, such as libraries of amino acid conformations, have enabled the development of advanced computational protein design tools. These computational tools can make complex calculations on protein energetics and flexibility, and perform searches over vast configuration spaces, which would be unfeasible to perform manually. Due to the development of computational protein design programs, and important successes in the field (see examples below), rational protein design has become one of the most important tools in protein engineering.",
            "score": 67.71355080604553
        },
        {
            "docid": "34567821_11",
            "document": "Critical Assessment of Function Annotation . The first CAFA experiment was organized between fall 2010 and spring 2012. The organizers provided 48,000 sequences for the community with the task to prediction Gene Ontology annotations for each of these sequences. Of those 48,000 proteins, 866 were experimentally annotated during target accumulation phase. The results showed that current function prediction algorithms perform significantly better than a simple domain assignment or a straightforward use of BLAST package. However, they also revealed that accurate prediction of a protein's biological function is still an open and challenging problem.",
            "score": 59.070817708969116
        },
        {
            "docid": "4007999_10",
            "document": "Immunogenicity . In silico screening. T cell epitope content, which is one of the factors that contributes to the risk of immunogenicity can now be measured relatively accurately using in silico tools. Immunoinformatics algorithms for identifying T-cell epitopes are now being applied to triage protein therapeutics into higher risk and low risk categories.",
            "score": 71.9773678779602
        },
        {
            "docid": "3112875_10",
            "document": "Computational immunology . There are also some computational models which focus on protein\u2013protein interactions and networks. There are also tools which are used for T and B cell epitope mapping, proteasomal cleavage site prediction, and TAP\u2013 peptide prediction. The experimental data is very much important to design and justify the models to predict various molecular targets. Computational immunology tools is the game between experimental data and mathematically designed computational tools.",
            "score": 47.697997093200684
        },
        {
            "docid": "3654507_29",
            "document": "Nuclear magnetic resonance spectroscopy of proteins . In addition to structures, nuclear magnetic resonance can yield information on the dynamics of various parts of the protein. This usually involves measuring relaxation times such as T and T to determine order parameters, correlation times, and chemical exchange rates. NMR relaxation is a consequence of local fluctuating magnetic fields within a molecule. Local fluctuating magnetic fields are generated by molecular motions. In this way, measurements of relaxation times can provide information of motions within a molecule on the atomic level. In NMR studies of protein dynamics the nitrogen-15 isotope is the preferred nucleus to study because its relaxation times are relatively simple to relate to molecular motions This, however, requires isotope labeling of the protein. The T and T relaxation times can be measured using various types of HSQC-based experiments. The types of motions that can be detected are motions that occur on a time-scale ranging from about 10 picoseconds to about 10 nanoseconds. In addition slower motions, which take place on a time-scale ranging from about 10 microseconds to 100 milliseconds, can also be studied. However, since nitrogen atoms are found mainly in the backbone of a protein, the results mainly reflect the motions of the backbone, which is the most rigid part of a protein molecule. Thus, the results obtained from nitrogen-15 relaxation measurements may not be representative for the whole protein. Therefore, techniques utilising relaxation measurements of carbon-13 and deuterium have recently been developed, which enables systematic studies of motions of the amino acid side-chains in proteins. A challenging and special case of study regarding dynamics and flexibility of peptides and full-length proteins is represented by disordered structures. Nowadays, it is an accepted concept that proteins can exhibit a more flexible behaviour known as disorder or lack of structure; however, it is possible to describe an ensemble of structures instead of a static picture representing a fully functional state of the protein. Many advances are represented in this field in particular in terms of new pulse sequences, technological improvement, and rigorous training of researchers in the field.",
            "score": 64.32716941833496
        },
        {
            "docid": "1581752_22",
            "document": "Protein design . The goal of protein design is to find a protein sequence that will fold to a target structure. A protein design algorithm must, thus, search all the conformations of each sequence, with respect to the target fold, and rank sequences according to the lowest-energy conformation of each one, as determined by the protein design energy function. Thus, a typical input to the protein design algorithm is the target fold, the sequence space, the structural flexibility, and the energy function, while the output is one or more sequences that are predicted to fold stably to the target structure.",
            "score": 49.72312617301941
        },
        {
            "docid": "1581752_2",
            "document": "Protein design . Protein design is the rational design of new protein molecules to design novel activity, behavior, or purpose, and to advance basic understanding of protein function. Proteins can be designed from scratch (\"de novo\" design) or by making calculated variants of a known protein structure and its sequence (termed \"protein redesign\"). Rational protein design approaches make protein-sequence predictions that will fold to specific structures. These predicted sequences can then be validated experimentally through methods such as peptide synthesis, site-directed mutagenesis, or artificial gene synthesis.",
            "score": 53.987123250961304
        },
        {
            "docid": "2916615_19",
            "document": "Force field (chemistry) . Another round of criticism came from practical applications, such as protein structure refinement. It was noted that \"Critical Assessment of protein Structure Prediction\" (CASP) participants did not try to refine their models to avoid \"\"a central embarrassment of molecular mechanics, namely that energy minimization or molecular dynamics generally leads to a model that is less like the experimental structure\"\". The force fields have been applied successfully for protein structure refinement in different X-ray crystallography and NMR spectroscopy applications, especially using program XPLOR. However, such refinement is driven mainly by a set of experimental constraints, whereas the interatomic potentials serve merely to remove interatomic hindrances. The results of calculations are practically the same with rigid sphere potentials implemented in program DYANA (calculations from NMR data), or with programs for crystallographic refinement that do not use any energy functions. The deficiencies of the interatomic potentials remain a major bottleneck in homology modeling of proteins. Such situation gave rise to development of alternative empirical scoring functions specifically for ligand docking, protein folding, homology model refinement, computational protein design, and modeling of proteins in membranes.",
            "score": 67.557452917099
        },
        {
            "docid": "866017_3",
            "document": "Genome@home . Following the Human Genome Project, scientists needed to know the biological and medical implications of the resulting wealth of genetic information. Genome@home used spare processing power on personal computers to virtually design genes that match existing proteins, although it can also design new proteins that have not been found in nature. This process is computationally demanding, so distributed computing is a viable option. Researchers can use the results from the project to gain a better understanding of the evolution of natural genomes and proteins, and their functionality. This project had applications in medical therapy, new pharmaceuticals, and assigning functions to newly sequenced genes.",
            "score": 68.45465993881226
        },
        {
            "docid": "14958_66",
            "document": "Immune system . Larger drugs (>500 Da) can provoke a neutralizing immune response, particularly if the drugs are administered repeatedly, or in larger doses. This limits the effectiveness of drugs based on larger peptides and proteins (which are typically larger than 6000 Da). In some cases, the drug itself is not immunogenic, but may be co-administered with an immunogenic compound, as is sometimes the case for Taxol. Computational methods have been developed to predict the immunogenicity of peptides and proteins, which are particularly useful in designing therapeutic antibodies, assessing likely virulence of mutations in viral coat particles, and validation of proposed peptide-based drug treatments. Early techniques relied mainly on the observation that hydrophilic amino acids are overrepresented in epitope regions than hydrophobic amino acids; however, more recent developments rely on machine learning techniques using databases of existing known epitopes, usually on well-studied virus proteins, as a training set. A publicly accessible database has been established for the cataloguing of epitopes from pathogens known to be recognizable by B cells. The emerging field of bioinformatics-based studies of immunogenicity is referred to as \"immunoinformatics\". Immunoproteomics is the study of large sets of proteins (proteomics) involved in the immune response.",
            "score": 89.76318645477295
        },
        {
            "docid": "4682359_5",
            "document": "Directed evolution . The first step in performing a cycle of directed evolution is the generation of a library of variant genes. The sequence space for random sequence is vast (10 possible sequences for a 100 amino acid protein) and extremely sparsely populated by functional proteins. Neither experimental, nor natural evolution can ever get close to sampling so many sequences. Of course, natural evolution samples variant sequences close to functional protein sequences and this is imitated in DE by mutagenising an already functional gene. Some calculations suggest it is entirely feasible that for all practical (i.e. functional and structural) purposes, protein sequence space has been fully explored during the course of evolution of life on Earth.",
            "score": 54.14547395706177
        },
        {
            "docid": "34567821_10",
            "document": "Critical Assessment of Function Annotation . The CAFA experiment is conducted by the Automated Function Prediction (AFP) Special Interest Group (AFP/SIG). An AFP/SIG meeting has been held alongside the Intelligent Systems for Molecular Biology conference in 2005, 2006, 2008, 2011, and 2012. The first CAFA experiment was organized between fall 2010 and spring 2012. The organizers provided 48,000 sequences for the community with the task to prediction Gene Ontology annotations for each of these sequences. Of those 48,000 proteins, 866 were experimentally annotated during target accumulation phase. The results showed that current function prediction algorithms perform significantly better than a simple domain assignment or a straightforward use of BLAST package. However, they also revealed that accurate prediction of a protein's biological function is still an open and challenging problem.",
            "score": 56.69999837875366
        },
        {
            "docid": "37760976_3",
            "document": "Infologs . Typical protein engineering methods rely on screening a high number (10-10 or more) of gene variants to identify individuals with improved activity using a surrogate high throughput screen (HTP) to identify initial hits. Unfortunately, results are defined by what is screened for, thus the \u201chit\u201d from the HTP screen often has very little real activity in a lower throughput assay more indicative of the improved functionality for which the protein is being developed. By adapting the standard algorithms for engineering complex systems to work with biological systems, the resulting process enables researchers to deconvolute how substitutions within a protein sequence modify its function. Combining these algorithms with an integrated query and ranking mechanism allows the identification of appropriate sequence substitutions. Infologs refers to the set of designed genes, singular use Infolog describes an individual variant.",
            "score": 69.08985137939453
        },
        {
            "docid": "1581752_44",
            "document": "Protein design . ILP solvers depend on linear programming (LP) algorithms, such as the Simplex or barrier-based methods to perform the LP relaxation at each branch. These LP algorithms were developed as general-purpose optimization methods and are not optimized for the protein design problem (Equation ()). In consequence, the LP relaxation becomes the bottleneck of ILP solvers when the problem size is large. Recently, several alternatives based on message-passing algorithms have been designed specifically for the optimization of the LP relaxation of the protein design problem. These algorithms can approximate both the dual or the primal instances of the integer programming, but in order to maintain guarantees on optimality, they are most useful when used to approximate the dual of the protein design problem, because approximating the dual guarantees that no solutions are missed. Message-passing based approximations include the \"tree reweighted max-product message passing\" algorithm, and the \"message passing linear programming\" algorithm.",
            "score": 63.22520077228546
        },
        {
            "docid": "969126_27",
            "document": "Protein structure . Protein structure database is a database that is modeled around the various experimentally determined protein structures. The aim of most protein structure databases is to organize and annotate the protein structures, providing the biological community access to the experimental data in a useful way. Data included in protein structure databases often includes 3D coordinates as well as experimental information, such as unit cell dimensions and angles for x-ray crystallography determined structures. Though most instances, in this case either proteins or a specific structure determinations of a protein, also contain sequence information and some databases even provide means for performing sequence based queries, the primary attribute of a structure database is structural information, whereas sequence databases focus on sequence information, and contain no structural information for the majority of entries. Protein structure databases are critical for many efforts in computational biology such as structure based drug design, both in developing the computational methods used and in providing a large experimental dataset used by some methods to provide insights about the function of a protein.",
            "score": 69.02129054069519
        },
        {
            "docid": "16784415_2",
            "document": "Protein structure database . In biology, a protein structure database is a database that is modeled around the various experimentally determined protein structures. The aim of most protein structure databases is to organize and annotate the protein structures, providing the biological community access to the experimental data in a useful way. Data included in protein structure databases often includes three-dimensional coordinates as well as experimental information, such as unit cell dimensions and angles for x-ray crystallography determined structures. Though most instances, in this case either proteins or a specific structure determinations of a protein, also contain sequence information and some databases even provide means for performing sequence based queries, the primary attribute of a structure database is structural information, whereas sequence databases focus on sequence information, and contain no structural information for the majority of entries. Protein structure databases are critical for many efforts in computational biology such as structure based drug design, both in developing the computational methods used and in providing a large experimental dataset used by some methods to provide insights about the function of a protein.",
            "score": 69.02129054069519
        },
        {
            "docid": "37760976_11",
            "document": "Infologs . Computational protein design algorithms seek to identify novel amino acid sequences that are low in energy when folded to the pre-specified target structure. While the sequence-conformation space that needs to be searched is large, the most challenging requirement for computational protein design is a fast, yet accurate, energy function that can distinguish optimal sequences from similar suboptimal ones.",
            "score": 62.11760604381561
        },
        {
            "docid": "35881441_3",
            "document": "HH-suite . Proteins are central players in all of life's processes. To understand how life in cells is organised, we have to understand what each of the proteins involved in these molecular processes does. This is particularly important in order to understand the origin of diseases. But for a large fraction of the approximately 20 000 human proteins the structures and functions remain unknown. Many proteins have been investigated in model organisms such as many bacteria, baker's yeast, fruit flies, zebra fish or mice, for which experiments can be often done more easily than with human cells. To predict the function, structure, or other properties of a protein for which only its sequence of amino acids is known, the protein sequence is compared to the sequences of other proteins in public databases. If a protein with sufficiently similar sequence is found, the two proteins are likely to be evolutionarily related (\"homologous\"). In that case, they are likely to share similar structures and functions. Therefore, if a protein with a sufficiently similar sequence and with known functions and/or structure can be found by the sequence search, the unknown protein's functions, structure, and domain composition can be predicted. Such predictions greatly facilitate the determination of the function or structure by targeted validation experiments.",
            "score": 61.271894216537476
        },
        {
            "docid": "1581752_15",
            "document": "Protein design . Rational protein design techniques must be able to discriminate sequences that will be stable under the target fold from those that would prefer other low-energy competing states. Thus, protein design requires accurate energy functions that can rank and score sequences by how well they fold to the target structure. At the same time, however, these energy functions must consider the computational challenges behind protein design. One of the most challenging requirements for successful design is an energy function that is both accurate and simple for computational calculations.",
            "score": 62.218549728393555
        },
        {
            "docid": "1581752_19",
            "document": "Protein design . Protein design, however, has requirements that can sometimes be limited in molecular mechanics force-fields. Molecular mechanics force-fields, which have been  used mostly in molecular dynamics simulations, are optimized for the simulation of single sequences, but protein design searches through many conformations of many sequences. Thus, molecular mechanics force-fields must be tailored for protein design. In practice, protein design energy functions often incorporate both statistical terms and physics-based terms. For example, the Rosetta energy function, one of the most-used energy functions, incorporates physics-based energy terms originating in the CHARMM energy function, and statistical energy terms, such as rotamer probability and knowledge-based electrostatics. Typically, energy functions are highly customized between laboratories, and specifically tailored for every design.",
            "score": 61.317609786987305
        },
        {
            "docid": "56710049_3",
            "document": "Off-target genome editing . Designer nuclease systems such as CRISPR-cas9 are becoming increasingly popular research tools as a result of their simplicity, scalability and affordability. With this being said, off-target genetic modifications are frequent and can alter the function of otherwise intact genes. Multiple studies using early CRISPR-cas9 agents found that greater than 50% of RNA-guided endonuclease-induced mutations were not occurring on-target. The Cas9 guide RNA (gRNA) recognizes a 20 bp target DNA sequence, which it binds and cleaves to \u2018edit\u2019 the DNA sequence. However, target sequence binding can tolerate mismatches up to several base pairs, meaning there are often thousands of possible binding sites which present several experimental and safety concerns. In the research sphere off-target effects can confound variables in biological studies leading to potentially misleading and non-reproducible results. In the clinical sphere the major concerns surround the disruption of vital coding regions leading to genotoxic effects such as cancer. Accordingly, the improvement of the specificity of genome editing tools and the detection of off-target effects are rapidly progressing research areas. Such research incorporates designer nuclease development and discovery, computational prediction programs and databases, and high-throughput sequencing to reduce and anticipate mutational occurrence. Many designer nuclease tools are still in their relative infancy and as their molecular properties and \"in vivo\" behaviors become better understood they will become increasingly precise and predictable.",
            "score": 40.757396817207336
        }
    ],
    "r": [
        {
            "docid": "4007999_13",
            "document": "Immunogenicity . De-immunization by epitope modification is a strategy for reducing immunogenicity based on disruption of HLA binding, an underlying requirement for T cell stimulation. The idea of rational epitope modification is rooted in the natural process that occurs when tumor cells and pathogens evolve to escape immune pressure by accumulating mutations that reduce the binding of their constituent epitopes to host HLA, rendering the host cell unable to \u201csignal\u201d to T cells the presence of the tumor or pathogen. Deimmunized protein therapeutics are now entering the clinic; initial results appear to support this approach to reducing immunogenicity risk. Several methods exist for deimmunization by epitope modification for reduced immunologic potential in-vitro, in-vivo and ex-vivo.",
            "score": 120.10606384277344
        },
        {
            "docid": "579414_2",
            "document": "Drug design . Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is sometimes referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of these protein-based therapeutics have also been developed.",
            "score": 90.68638610839844
        },
        {
            "docid": "14958_66",
            "document": "Immune system . Larger drugs (>500 Da) can provoke a neutralizing immune response, particularly if the drugs are administered repeatedly, or in larger doses. This limits the effectiveness of drugs based on larger peptides and proteins (which are typically larger than 6000 Da). In some cases, the drug itself is not immunogenic, but may be co-administered with an immunogenic compound, as is sometimes the case for Taxol. Computational methods have been developed to predict the immunogenicity of peptides and proteins, which are particularly useful in designing therapeutic antibodies, assessing likely virulence of mutations in viral coat particles, and validation of proposed peptide-based drug treatments. Early techniques relied mainly on the observation that hydrophilic amino acids are overrepresented in epitope regions than hydrophobic amino acids; however, more recent developments rely on machine learning techniques using databases of existing known epitopes, usually on well-studied virus proteins, as a training set. A publicly accessible database has been established for the cataloguing of epitopes from pathogens known to be recognizable by B cells. The emerging field of bioinformatics-based studies of immunogenicity is referred to as \"immunoinformatics\". Immunoproteomics is the study of large sets of proteins (proteomics) involved in the immune response.",
            "score": 89.76318359375
        },
        {
            "docid": "4007999_12",
            "document": "Immunogenicity . Using this approach, the clinical immunogenicity of a novel protein therapeutics can be calculated and consequently a number of biotech companies have integrated in silico immunogenicity into their pre-clinical process as they develop new protein drugs.",
            "score": 87.53015899658203
        },
        {
            "docid": "21723923_4",
            "document": "Reverse phase protein lysate microarray . Multiplexing is achieved by probing multiple arrays spotted with the same lysate with different antibodies simultaneously and can be implemented as a quantitative calibrated assay. In addition, since RPMA can utilize whole-cell or undissected or microdissected cell lysates, it can provide direct quantifiable information concerning post translationally modified proteins that are not accessible with other high-throughput techniques. Thus, RPMA provides high-dimensional proteomic data in a high throughput, sensitive and quantitative manner. However, since the signal generated by RPMA could be generated from unspecific primary or secondary antibody binding, as is seen in other techniques such as ELISA, or immunohistochemistry, the signal from a single spot could be due to cross-reactivity. Thus, the antibodies used in RPMA must be carefully validated for specificity and performance against cell lysates by western blot.  RPMA has various uses such as quantitative analysis of protein expression in cancer cells, body fluids or tissues for biomarker profiling, cell signaling analysis and clinical prognosis, diagnosis or therapeutic prediction. This is possible as a RPMA with lysates from different cell lines and or laser capture microdissected tissue biopsies of different disease stages from various organs of one or many patients can be constructed for determination of relative or absolute abundance or differential expression of a protein marker level in a single experiment. It is also used for monitoring protein dynamics in response to various stimuli or doses of drugs at multiple time points. Some other applications that RPMA is used for include exploring and mapping protein signaling pathways, evaluating molecular drug targets and understanding a candidate drug\u2019s mechanism of action. It has been also suggested as a potential early screen test in cancer patients to facilitate or guide therapeutic decision making.",
            "score": 87.3995361328125
        },
        {
            "docid": "413102_8",
            "document": "Folding@home . Protein misfolding can result in a variety of diseases including Alzheimer's disease, cancer, Creutzfeldt\u2013Jakob disease, cystic fibrosis, Huntington's disease, sickle-cell anemia, and type\u00a0II diabetes. Cellular infection by viruses such as HIV and influenza also involve folding events on cell membranes. Once protein misfolding is better understood, therapies can be developed that augment cells' natural ability to regulate protein folding. Such therapies include the use of engineered molecules to alter the production of a given protein, help destroy a misfolded protein, or assist in the folding process. The combination of computational molecular modeling and experimental analysis has the possibility to fundamentally shape the future of molecular medicine and the rational design of therapeutics, such as expediting and lowering the costs of drug discovery. The goal of the first five years of Folding@home was to make advances in understanding folding, while the current goal is to understand misfolding and related disease, especially Alzheimer's.",
            "score": 86.7521743774414
        },
        {
            "docid": "1004486_3",
            "document": "Pharmacogenomics . Pharmacogenomics aims to develop rational means to optimize drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects. Through the utilization of pharmacogenomics, it is hoped that pharmaceutical drug treatments can deviate from what is dubbed as the \"one-dose-fits-all\" approach. Pharmacogenomics also attempts to eliminate the trial-and-error method of prescribing, allowing physicians to take into consideration their patient's genes, the functionality of these genes, and how this may affect the efficacy of the patient's current or future treatments (and where applicable, provide an explanation for the failure of past treatments). Such approaches promise the advent of precision medicine and even personalized medicine, in which drugs and drug combinations are optimized for narrow subsets of patients or even for each individual's unique genetic makeup. Whether used to explain a patient's response or lack thereof to a treatment, or act as a predictive tool, it hopes to achieve better treatment outcomes, greater efficacy, minimization of the occurrence of drug toxicities and adverse drug reactions (ADRs). For patients who have lack of therapeutic response to a treatment, alternative therapies can be prescribed that would best suit their requirements. In order to provide pharmacogenomic recommendations for a given drug, two possible types of input can be used: genotyping or exome or whole genome sequencing. Sequencing provides many more data points, including detection of mutations that prematurely terminate the synthesized protein (early stop codon).",
            "score": 81.71430969238281
        },
        {
            "docid": "17310564_6",
            "document": "Keyhole limpet hemocyanin . Keyhole limpet hemocyanin (KLH) is used extensively as a carrier protein in the production of antibodies for research, biotechnology and therapeutic applications. Haptens are substances with a low molecular weight such as peptides, small proteins and drug molecules that are generally not immunogenic and require the aid of a carrier protein to stimulate a response from the immune system in the form of antibody production. KLH is the most widely employed carrier protein for this purpose. KLH is an effective carrier protein for several reasons. Its large size and numerous epitopes generate a substantial immune response, and abundance of lysine residues for coupling haptens allows a high hapten:carrier protein ratio, increasing the likelihood of generating hapten-specific antibodies. In addition, because KLH is derived from the limpet, a gastropod, it is phylogenetically distant from mammalian proteins, thus reducing false positives in immunologically-based research techniques in mammalian model organisms.",
            "score": 81.64708709716797
        },
        {
            "docid": "106256_31",
            "document": "Allosteric regulation . Allostery is a direct and efficient means for regulation of biological macromolecule function, produced by the binding of a ligand at an allosteric site topographically distinct from the orthosteric site. Due to the often high receptor selectivity and lower target-based toxicity, allosteric regulation is also expected to play an increasing role in drug discovery and bioengineering. The AlloSteric Database (ASD, http://mdl.shsmu.edu.cn/ASD) provides a central resource for the display, search and analysis of the structure, function and related annotation for allosteric molecules. Currently, ASD contains allosteric proteins from more than 100 species and modulators in three categories (activators, inhibitors, and regulators). Each protein is annotated with detailed description of allostery, biological process and related diseases, and each modulator with binding affinity, physicochemical properties and therapeutic area. Integrating the information of allosteric proteins in ASD should allow the prediction of allostery for unknown proteins, to be followed with experimental validation. In addition, modulators curated in ASD can be used to investigate potential allosteric targets for a query compound, and can help chemists to implement structure modifications for novel allosteric drug design.",
            "score": 80.8609619140625
        },
        {
            "docid": "216104_20",
            "document": "Protein engineering . Natural Darwinian evolution can be effectively imitated in the lab toward tailoring protein properties for diverse applications, including catalysis. Many experimental technologies exist to produce large and diverse protein libraries and for screening or selecting folded, functional variants. Folded proteins arise surprisingly frequently in random sequence space, an occurrence exploitable in evolving selective binders and catalysts. While more conservative than direct selection from deep sequence space, redesign of existing proteins by random mutagenesis and selection/screening is a particularly robust method for optimizing or altering extant properties. It also represents an excellent starting point for achieving more ambitious engineering goals. Allying experimental evolution with modern computational methods is likely the broadest, most fruitful strategy for generating functional macromolecules unknown to nature.",
            "score": 79.9078140258789
        },
        {
            "docid": "1581752_26",
            "document": "Protein design . Several algorithms have been developed specifically for the protein design problem. These algorithms can be divided into two broad classes: exact algorithms, such as dead-end elimination, that lack runtime guarantees but guarantee the quality of the solution; and heuristic algorithms, such as Monte Carlo, that are faster than exact algorithms but have no guarantees on the optimality of the results. Exact algorithms guarantee that the optimization process produced the optimal according to the protein design model. Thus, if the predictions of exact algorithms fail when these are experimentally validated, then the source of error can be attributed to the energy function, the allowed flexibility, the sequence space or the target structure (e.g., if it cannot be designed for)",
            "score": 78.83851623535156
        },
        {
            "docid": "30351926_3",
            "document": "ASD (database) . Allosteric Database (ASD) provides a central resource for the display, search and analysis of the structure, function and related annotation for allosteric molecules. Currently, ASD contains allosteric proteins from more than 100 species and modulators in three categories (activators, inhibitors, and regulators). Each protein is annotated with a detailed description of allostery, biological process and related diseases, and each modulator with binding affinity, physicochemical properties and therapeutic area. Integrating the information of allosteric proteins in ASD should allow for the prediction of allostery for unknown proteins and eventually make them ideal targets for experimental validation. In addition, modulators curated in ASD can be used to investigate potent allosteric targets for the query compound, and also help chemists implement structure modifications for novel allosteric drug designs. Therefore, ASD could be a platform and a starting point for biologists and medicinal chemists for furthering allosteric research.",
            "score": 78.54003143310547
        },
        {
            "docid": "4007999_5",
            "document": "Immunogenicity . In the rush to deliver novel biologics to market, developers have, on occasion, overlooked factors that contribute to protein immunogenicity. In addition, autologous or human-like proteins have proven to be surprisingly immunogenic in some applications, suggesting that assumptions about immune tolerance, too, require careful consideration in biologics design.",
            "score": 78.29212188720703
        },
        {
            "docid": "11344743_5",
            "document": "Biomolecular engineering . Bio-inspired technologies of the future can help explain biomolecular engineering. Looking at the Moore's law \"Prediction\", in the future quantum and biology-based processors are \"big\" technologies. With the use of biomolecular engineering, the way our processors work can be manipulated in order to function in the same sense a biological cell work. Biomolecular engineering has the potential to become one of the most important scientific disciplines because of its advancements in the analyses of gene expression patterns as well as the purposeful manipulation of many important biomolecules to improve functionality. Research in this field may lead to new drug discoveries, improved therapies, and advancement in new bioprocess technology. With the increasing knowledge of biomolecules, the rate of finding new high-value molecules including but not limited to antibodies, enzymes, vaccines, and therapeutic peptides will continue to accelerate. Biomolecular engineering will produce new designs for therapeutic drugs and high-value biomolecules for treatment or prevention of cancers, genetic diseases, and other types of metabolic diseases. Also, there is anticipation of industrial enzymes that are engineered to have desirable properties for process improvement as well the manufacturing of high-value biomolecular products at a much lower production cost. Using recombinant technology, new antibiotics that are active against resistant strains will also be produced.",
            "score": 77.63691711425781
        },
        {
            "docid": "2161878_45",
            "document": "Protein\u2013protein interaction . RNA interference (RNAi) screens (repression of individual proteins between transcription and translation) are one method that can be utilized in the process of providing signs to the protein-protein interactions. Individual proteins are repressed and the resulting phenotypes are analyzed. A correlating phenotypic relationship (i.e. where the inhibition of either of two proteins results in the same phenotype) indicates a positive, or activating relationship. Phenotypes that do not correlate (i.e. where the inhibition of either of two proteins results in two different phenotypes) indicate a negative or inactivating relationship. If protein A is dependent on protein B for activation then the inhibition of either protein A or B will result in a cell losing the service that is provided by protein A and the phenotypes will be the same for the inhibition of either A or B. If, however, protein A is inactivated by protein B then the phenotypes will differ depending on which protein is inhibited (inhibit protein B and it can no longer inactivate protein A leaving A active however inactivate A and there is nothing for B to activate since A is inactive and the phenotype changes). Multiple RNAi screens need to be performed in order to reliably appoint a sign to a given protein-protein interaction. Vinayagam et al. who devised this technique state that a minimum of nine RNAi screens are required with confidence increasing as one carries out more screens. Modulation of PPI is challenging and is receiving increasing attention by the scientific community. Several properties of PPI such as allosteric sites and hotspots, have been incorporated into drug-design strategies. The relevance of PPI as putative therapeutic targets for the development of new treatments is particularly evident in cancer, with several ongoing clinical trials within this area. The consensus among these promising targets is, nonetheless, denoted in the already available drugs on the market to treat a multitude of diseases. Examples are Titrobifan, inhibitor of the glycoprotein IIb/IIIa, used as a cardiovascular drug, and Maraviroc, inhibitor of the CCR5-gp120 interaction, used as anti-HIV drug. Recently, Amit Jaiswal and others were able to develop 30 peptides using protein\u2013protein interaction studies to inhibit telomerase recruitment towards telomeres.",
            "score": 77.4519271850586
        },
        {
            "docid": "39284674_2",
            "document": "Plant manufactured pharmaceuticals . Plant Manufactured Pharmaceuticals are pharmaceuticals derived from genetically modified plants used as therapeutic compounds. This can be used as the replacement for the traditional method of inoculating animals for Cell Culture production. We can use plants to cure and prevent diseases that may have once been deemed incurable. Through biotechnological advancements, we are able to produce complex therapeutic proteins from plant cells. Such Therapeutic Proteins are seen in brands like Enevrel and Remicade for rheumatoid arthritis, Herceptin, a breast cancer treatment. Plants like tobacco are hosts for protein production for applications such as; anemia, hepatitis C & B, hypertension, antimicrobial, and liver disease.",
            "score": 77.337158203125
        },
        {
            "docid": "1111019_16",
            "document": "Polyclonal antibodies . Selection of antigen quantity for immunization varies with the properties of the antigen and the adjuvant selected. In general, microgram to milligram quantities of protein in adjuvant are necessary to elicit high titer antibodies. Antigen dosage is generally species, rather than body weight, associated. The so-called \u201cwindow\u201d of immunogenicity in each species is broad but too much or too little antigen can induce tolerance, suppression or immune deviation towards cellular immunity rather than a satisfactory humoral response. Optimal and usual protein antigen levels for immunizing specific species have been reported in the following ranges: Optimal \u201cpriming\u201d doses are reported to be at the low end of each range.",
            "score": 76.9548568725586
        },
        {
            "docid": "4007999_7",
            "document": "Immunogenicity . Like vaccines, protein therapeutics can engender both cellular and humoral immune responses. Anti-drug antibodies (ADA) may neutralize the therapeutic effects of the drug and/or alter its pharmacokinetics. B cells are certainly involved in this immune response when IgG class ADA are observed, because antibody isotype switching is a hallmark of B-dependent antigens.",
            "score": 76.91812896728516
        },
        {
            "docid": "216104_4",
            "document": "Protein engineering . In rational protein design, a scientist uses detailed knowledge of the structure and function of a protein to make desired changes. In general, this has the advantage of being inexpensive and technically easy, since site-directed mutagenesis methods are well-developed. However, its major drawback is that detailed structural knowledge of a protein is often unavailable, and, even when available, it can be very difficult to predict the effects of various mutations since structural information most often provide a static picture of a protein structure. However, programs such as Folding@home and Foldit have utilized crowdsourcing techniques in order to gain insight into the folding motifs of proteins.  Computational protein design algorithms seek to identify novel amino acid sequences that are low in energy when folded to the pre-specified target structure. While the sequence-conformation space that needs to be searched is large, the most challenging requirement for computational protein design is a fast, yet accurate, energy function that can distinguish optimal sequences from similar suboptimal ones.",
            "score": 76.59114837646484
        },
        {
            "docid": "4007999_6",
            "document": "Immunogenicity . Fortunately, years of thorough study of the parameters influencing vaccine efficacy allow parallels to be drawn for protein therapeutics. Factors including delivery route, delivery vehicle, dose regimen, aggregation, innate immune system activation, and the ability of the protein to interface with the humoral (B cell) and cellular (T cell) immune systems, all impact the potential immunogenicity of vaccine immunogens when delivered to humans (for reviews related to unwanted immunogenicity determinants, see references below).",
            "score": 76.37690734863281
        },
        {
            "docid": "159010_20",
            "document": "Tacrolimus . The predominant enzyme responsible for metabolism of tacrolimus is CYP3A5. Genetic variations within \"CYP3A5\" that result in changes to the activity of the CYP3A5 protein can affect concentrations of tacrolimus within the body. In particular, individuals who are homozygous for the G allele at the single nucleotide polymorphism (SNP) rs776746 (also known as CYP3A5 *3/*3) have a non-functional CYP3A5 protein. The frequency of the G allele varies worldwide, from 4% in some African populations to 80\u201390% in Caucasian populations. Across a large number of studies, individuals homozygous for the G allele have been shown to have higher concentrations of tacrolimus and require lower doses of the drug, as compared to individuals who are not homozygous for the G allele. Achieving target concentrations of tacrolimus is important \u2013 if levels are too low, then there is a risk of transplant rejection, if levels are too high, there is a risk of drug toxicities. There is evidence to suggest that dosing patients based on rs776746 genotype can result in faster and more frequent achievement of target tacrolimus levels. However, there is a lack of consistent evidence as to whether dosing based on rs776746 genotype results in improved clinical outcomes (such as a decreased risk for transplant rejection or drug toxicities), likely because patients taking tacrolimus are subject to therapeutic drug monitoring.",
            "score": 75.91943359375
        },
        {
            "docid": "31776829_8",
            "document": "Hsp90 inhibitor . HSP90 is gaining increasing importance as a cancer target, in large part because of the potential for combinatorial targeting of multiple oncogenic protein pathways and biological effects. The good tolerability seen with the first-in-class drug 17-AAG has encouraged many biotechnology and large pharma companies to enter the field. The ability to demonstrate proof of concept for target modulation in patients has also been encouraging, as has the early evidence of clinical activity in melanoma 17-AAG is now in Phase II studies as a single agent and combination studies with cytotoxic and other agents such as the proteasome inhibitor bortezomib are also underway. Improved formulations for parenteral use are also being evaluated in the clinic. Radicicol-based inhibitors have not entered clinical development. Following on from the initial proof of concept studies with the natural product agents, considerable progress has been made in the preclinical development of small molecule, synthetic inhibitors, as exemplified by the purine and pyrazole based compounds. The recent rapid progress has built on a wealth of knowledge obtained with the natural product inhibitors and is a good example of the value of chemical biology studies in which the biological activity is identified first and then the molecular target is discovered by detailed biological studies. Current medicinal chemistry activities are focusing on the combined use of high throughput screening and structure-based design, coupled to the evaluation of the compounds in robust and mechanistically- informative biological assays. The next decade will be exciting in the HSP90 field as the clinical activity of the early geldanamycin-based drugs is rigorously evaluated while a series of synthetic small-molecule agents enter preclinical and clinical development. Particular areas of interest will include the potential for orally active HSP90 inhibitors and for the development of isoform-selective drugs that are targeted to particular members of the HSP90 family (DMAG \u2013N-OXIDE). HSP90 inhibitors may also be evaluated in diseases other than cancer and where protein folding defects are involved in the disease pathology. It can be predicted that additional molecular chaperones will now be targeted for therapeutic intervention in cancer and other diseases. Furthermore, a portfolio of drugs can be envisaged that target various points in the protein quality control pathways of the malignant cell and other diseases states.",
            "score": 75.55437469482422
        },
        {
            "docid": "13975479_17",
            "document": "RHOA . Protein expression of RhoA has been identified to be significantly higher in testicular tumor tissue than that in nontumor tissue; expression of protein for RhoA, ROCK-I, ROCK-II, Rac1, and Cdc42 was greater in tumors of higher stages than lower stages, coinciding with greater lymph metastasis and invasion in upper urinary tract cancer. Although both RhoA and RhoC proteins comprise a significant part of the Rho GTPases that are linked to promoting the invasive behavior of breast carcinomas, attributing specific functions to these individual members has been difficult. We have used a stable retroviral RNA interference approach to generate invasive breast carcinoma cells (SUM-159 cells) that lack either RhoA or RhoC expression. Analysis of these cells enabled us to deduce that RhoA impedes and RhoC stimulates invasion. Unexpectedly, this analysis also revealed a compensatory relationship between RhoA and RhoC at the level of both their expression and activation, and a reciprocal relationship between RhoA and Rac1 activation. Chronic Myeloid Leukemia (CML), a stem cell disorder that prevents myeloid cells from functioning correctly, has been linked to actin polymerization. Signaling proteins like RhoA, regulate polymerization of actin. Due to differences proteins exhibited between normal and affected neutrocytes, RhoA has become the key element; further experimentation has also shown that RhoA-inhibiting pathways prevent the overall growth of CML cells. As a result, RhoA has significant potential as a therapeutic target in gene therapy techniques to treating CML. Therefore, RhoA\u2019s role in the proliferation of cancer cell phenotypes is a key application that can be applied to targeted cancer therapeutics and the development for pharmaceuticals.",
            "score": 75.5356216430664
        },
        {
            "docid": "10931846_2",
            "document": "PEGylation . PEGylation (often styled pegylation) is the process of both covalent and non-covalent attachment or amalgamation of polyethylene glycol (PEG, in pharmacy called macrogol) polymer chains to molecules and macrostructures, such as a drug, therapeutic protein or vesicle, which is then described as PEGylated (pegylated). PEGylation is routinely achieved by the incubation of a reactive derivative of PEG with the target molecule. The covalent attachment of PEG to a drug or therapeutic protein can \"mask\" the agent from the host's immune system (reducing immunogenicity and antigenicity), and increase its hydrodynamic size (size in solution), which prolongs its circulatory time by reducing renal clearance. PEGylation can also provide water solubility to hydrophobic drugs and proteins. Having proven its pharmacological advantages and acceptability, PEGylation technology is the foundation of a growing multibillion-dollar industry.",
            "score": 75.15115356445312
        },
        {
            "docid": "4007999_11",
            "document": "Immunogenicity . One approach is to parse protein sequences into overlapping 9-mer peptide frames, each of which is then evaluated for binding potential to each of eight common class II HLA alleles that \u201ccover\u201d the genetic backgrounds of most humans worldwide. By calculating the density of high-scoring frames within a protein, it is possible to estimate a protein\u2019s overall \u201cimmunogenicity score\u201d. In addition, sub-regions of densely packed high scoring frames or \u201cclusters\u201d of potential immunogenicity can be identified, and cluster scores can be calculated and compiled. Given the resulting \u201cimmunogenicity score\u201d of a protein, and taking into consideration other determinants of immunogenicity as described above, it is possible to make an informed decision about the likelihood that a protein will provoke an immune response.",
            "score": 74.79499053955078
        },
        {
            "docid": "7172_74",
            "document": "Chemotherapy . Targeted therapies are a relatively new class of cancer drugs that can overcome many of the issues seen with the use of cytotoxics. They are divided into two groups: small molecule and antibodies. The massive toxicity seen with the use of cytotoxics is due to the lack of cell specificity of the drugs. They will kill any rapidly dividing cell, tumor or normal. Targeted therapies are designed to affect cellular proteins or processes that are utilised by the cancer cells. This allows a high dose to cancer tissues with a relatively low dose to other tissues. Although the side effects are often less severe than that seen of cytotoxic chemotherapeutics, life-threatening effects can occur. Initially, the targeted therapeutics were supposed to be solely selective for one protein. Now it is clear that there is often a range of protein targets that the drug can bind. An example target for targeted therapy is the protein produced by the Philadelphia chromosome, a genetic lesion found commonly in chronic myelomonocytic leukemia. This fusion protein has enzyme activity that can be inhibited by imatinib, a small molecule drug.",
            "score": 74.42677307128906
        },
        {
            "docid": "42057374_3",
            "document": "Chem-seq . A substantial number of small-molecule ligands, including therapeutic drugs, elicit their effects by binding specific proteins associated with the genome. Mapping the global interactions of these chemical entities with chromatin in a genome-wide manner could provide insights into the mechanisms by which a small molecule influences cellular functions. When combined with other chromatin analysis techniques such as ChIP-seq, Chem-seq can be utilized to investigate the genome-wide effects of therapeutic modalities and to understand the effects of drugs on nuclear architecture in various biological contexts. In a broader sense, these methods will be useful to enhance our understanding of the therapeutic mechanisms through which small molecules modulate the function and activity of genome-associated proteins. Through the identification of the cellular targets of a drug, it becomes possible to gain an increased understanding of the causes of side effects and toxicity in the early stages of drug development, which should help to reduce the attrition rate in development.",
            "score": 74.4120864868164
        },
        {
            "docid": "20358421_2",
            "document": "Target protein . Target proteins are functional biomolecules that are addressed and controlled by biologically active compounds. They are used in the processes of transduction, transformation and conjugation. The identification of target proteins, the investigation of signal transduction processes and the understanding of their interaction with ligands are key elements of modern biomedical research. Since the interaction with target proteins is the molecular origin of most drugs, their particular importance for molecular biology, molecular pharmacy and pharmaceutical sciences is obvious. Target proteins control the action and the kinetic behavior of drugs within the organism. The elucidation of structure, conformational signaling and catalytic properties of particular target proteins facilitates a rational design of drugs and biotechnological processes. Known as biologicals, target proteins can also be drugs by themselves when their modification and formulation is emphasized within the pharmaceutical sciences. Finally, target protein - inducer interactions can be exploited for biomolecular transcription regulating systems in order to control for example gene therapeutic approaches.",
            "score": 74.33959197998047
        },
        {
            "docid": "64972_27",
            "document": "Angiogenesis . Angiogenesis represents an excellent therapeutic target for the treatment of cardiovascular disease. It is a potent, physiological process that underlies the natural manner in which our bodies respond to a diminution of blood supply to vital organs, namely the production of new collateral vessels to overcome the ischemic insult. A large number of preclinical studies have been performed with protein-, gene- and cell-based therapies in animal models of cardiac ischemia, as well as models of peripheral artery disease. Reproducible and credible successes in these early animal studies led to high enthusiasm that this new therapeutic approach could be rapidly translated to a clinical benefit for millions of patients in the Western world suffering from these disorders. A decade of clinical testing both gene- and protein-based therapies designed to stimulate angiogenesis in underperfused tissues and organs, however, has led from one disappointment to another. Although all of these preclinical readouts, which offered great promise for the transition of angiogenesis therapy from animals to humans, were in one fashion or another, incorporated into early stage clinical trials, the FDA has, to date (2007), insisted that the primary endpoint for approval of an angiogenic agent must be an improvement in exercise performance of treated patients.",
            "score": 74.12355041503906
        },
        {
            "docid": "44764475_8",
            "document": "Aldehyde tag . The aldehyde tag is a technique which recently found increased application because of the introduction of bioorthogonal chemical reporters. Bioorthogonal agents contain functional groups such as azides or cyclooctynes for coupling which are not naturally found in the cell. Due to their foreignness, they seem inert and do not disrupt the native metabolism,  Fig. 3 gives an overview of possible labelling methods for formylglycine. For example, it can be coupled to probes such as biotin or a protein tag like Flag that are useful for purification and detection. Furthermore, fluorophores can be directly conjugated for live cell imaging. The conjugation of polyethylene glycol (PEG) chains to potential drug candidates extends the stability against proteases in body fluids and at the same time reduces renal clearance and immunogenicity. The first application described here, deals with the formation of protein-protein conjugates through bioorthogonal probes. Since, the aldehyde tag is strictly speaking not a true bioorthogonal agent as it can be found in various metabolites, it can cause cross reactions during protein labelling. However, coupling bioorthogonal probes such as azides or cycloctynes can be applied to overcome this obstacle. As a second application, the coupling of glycan moieties to proteins is presented here. It can be utilised in the strategy of chemically introduced glycosylation patterns.",
            "score": 73.911376953125
        },
        {
            "docid": "32663259_7",
            "document": "Gregorio Weber . Gregorio Weber\u2019s original and lifelong motivation was to use fluorescence methods to probe the nature of proteins and in addition to his contributions to the fluorescence field, he was one of the true pioneers of protein dynamics. A study of his papers from the 1960s demonstrates that even then he regarded proteins as highly dynamic molecules. He rejected the view, common at that time after the appearance of the first x-ray structures, that proteins had a unique and rigid conformation. In an important innovation, he introduced the use of molecular oxygen to quench fluorescence in aqueous solutions, which led to the detection, for the first time and to the surprise of many, of the existence of fast fluctuations in protein structures on the nanosecond time scale. The impact of this work was shown by the increasing interest in experimental and theoretical work in protein dynamics, which followed. Weber\u2019s early description of proteins in solution as \u201ckicking and screaming stochastic molecules\u201d has, in recent years, been fully verified both from theoretical and experimental studies. These contributions were recognized by the American Chemical Society in 1986, which named Weber as the first recipient of Repligen Award for the Chemistry of Biological Processes. In the 1970s, initially in collaboration with H.G. Drickamer, Weber combined fluorescence and hydrostatic pressure methods to the study of molecular complexes and proteins. The initial system he thought to study was the complex formed by isoalloxazine and adenine, one of his original research interests. These observations confirmed the applicability of fluorescence and high-pressure techniques to problems of structure, and particularly dynamics, at the molecular level. Weber and collaborators demonstrated that most proteins made up of subunits can be dissociated by the application of hydrostatic pressure, and opened, in this way, a new method to study protein-protein interactions. In these studies, quite unexpected properties of protein aggregates were revealed and a new approach to problems in biology and medicine was opened by these observations. For example, Weber and his collaborators demonstrated the possibility of destroying the infectivity of viruses, without affecting their immunogenic capacity, by subjecting them to hydrostatic pressure, and thus opened the possibility of developing viral vaccines that contain, without covalent modification, all the antigens present in the original virus.",
            "score": 73.64163208007812
        },
        {
            "docid": "6330972_25",
            "document": "Therapeutic gene modulation . Designer zinc-finger proteins, on the other hand, have undergone some trials in the clinical arena. The efficacy and safety of EW-A-401, an engineered zinc-finger transcription factor, as a pharmacologic agent for treating claudication, a cardiovascular ailment, has been investigated in clinical trials. The protein consists of an engineered plasmid DNA that prompts the patient to produce an engineered transcription factor, the target of which is the vascular endothelial growth factor-A (VEGF-A) gene, which positively influences blood vessel development. Although not yet approved by the U.S. Food and Drug Administration (FDA), two Phase I clinical studies have been completed which identify this zinc-finger protein as a promising and safe potential therapeutic agent for treatment of peripheral arterial disease in humans.",
            "score": 73.37792205810547
        }
    ]
}